M.D. Anderson Events

Pediatrics Research Seminar Series: Targeting the Fas/Fas L Pathway with Aerosol Gemcitibine

Eugenie S. Kleinerman, M.D.

Professor and Head, Division of Pediatrics, Professor, Department of Cancer Biology, Mosbacher Pediatrics Chair

This series covers basic and translational research in cancer, with a primary focus on pediatric tumors. Researchers present on a wide variety of topics ranging from Developmental Biology to Apoptosis to Cell Signaling.

Date: 8/18/09, 9am to 10am
Time: 8/18/09, 9am to 10am
Location: Smith Research Building, Conference SRB1.122
Format: Seminar/Conference
Speaker Bio: Eugenie (Genie) S. Kleinerman, M.D., professor and head of the Division of Pediatrics, is the first woman division head at M. D. Anderson Cancer Center. She is board certified in pediatrics, holds the Mosbacher Pediatrics Chair and is also a professor of cancer biology. A native of Cleveland, Ohio, Dr. Kleinerman received her B.A. degree from Washington University in St. Louis and her medical degree from Duke University. She completed her pediatric residency at the Children's Hospital National Medical Center in Washington, D.C., and her fellowship at the National Cancer Institute in Bethesda, MD. She was a senior investigator at the NCI-Frederick Cancer Research facility for three years before being recruited to M. D. Anderson in 1984, by Dr. Josh Fidler, former chair of Cancer Biology. Dr. Kleinerman is internationally recognized for her scientific and clinical expertise in sarcomas, particularly osteosarcoma. She pioneered the use of a unique immunotherapy agent liposome-encapsulated MTP-PE, for children with unresponsive relapsed osteosarcoma lung metastases. Her phase II clinical trials done at M. D. Anderson demonstrated that liposomal MTP-PE therapy activated the tumoricidal properties of macrophages, prolonged disease-free survival and could be combined with chemotherapy. The success of these trials led to a national phase III trial sponsored by the Children's Oncology Group. Newly diagnosed osteosarcoma patients treated with liposomal MTP-PE plus chemotherapy has a 30% reduction in mortality rate compared to the patients that received chemotherapy alone. This demonstration of efficacy led to the recent approval of liposomal MTP-PE by the European Medicine Agency, which is now available in 27 countries in the European Union.
Contact: Samuel Riley - (713) 563-5394 - sriley@mdanderson.org

Add event to my calendar